SNBL backs U.S. launch build-out for migraine drug Atzumi after licensing talks stall

Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ) has issued an announcement.

Shin Nippon Biomedical Laboratories has outlined a new commercialization strategy for Atzumi, an intranasal dihydroergotamine therapy developed by U.S. subsidiary Satsuma Pharmaceuticals for acute migraine in adults. After securing FDA approval and failing to secure an out-licensing deal on acceptable terms, the company turned to Trinity Life Sciences to validate the U.S. migraine market opportunity and potential go-to-market options.

Trinity’s analysis highlighted a concentrated prescriber base and a sizable second-line segment of patients not adequately served by existing treatments, supporting Satsuma’s projection that Atzumi’s peak sales could exceed USD 200 million. SNBL will now back Satsuma in building its own manufacturing and commercialization infrastructure for an early U.S. launch while pursuing ex-U.S. partnerships, a move that front-loads investment costs and contributes to a projected larger operating loss in the year to March 2027 but aims to maximize long-term value from the asset.

The most recent analyst rating on (JP:2395) stock is a Buy with a Yen1780.00 price target. To see the full list of analyst forecasts on Shin Nippon Biomedical Laboratories, Ltd. stock, see the JP:2395 Stock Forecast page.

More about Shin Nippon Biomedical Laboratories, Ltd.

Shin Nippon Biomedical Laboratories, Ltd. is a Japan-based contract research and drug development company listed on the TSE Prime, with activities spanning preclinical and clinical services and proprietary technologies for pharmaceutical clients. Through its U.S. consolidated subsidiary Satsuma Pharmaceuticals, Inc., it is advancing migraine therapies that leverage SMART, its intranasal powder and device platform, to address unmet needs in acute migraine treatment.

Average Trading Volume: 211,037

Technical Sentiment Signal: Sell

Current Market Cap: Yen59.74B

See more insights into 2395 stock on TipRanks’ Stock Analysis page.